Arthur Vermeulen, MD
Internal Medicine · Los Angeles, CANPI 1598324055
Payments from drug & device makers
Across 307 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$1K
- EMD Serono, Inc.$553
- Merck$389
- AbbVie$342
- Amgen$288
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,140100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 90 | $2,678 |
| Gilead | 43 | $1,214 |
| EMD Serono, Inc. | 23 | $553 |
| Merck | 17 | $389 |
| AbbVie | 15 | $342 |
| Amgen | 8 | $288 |
| Theratechnologies Inc. | 5 | $258 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $247 |
| Axsome Therapeutics, Inc. | 10 | $244 |
| Johnson & Johnson | 6 | $242 |
| Corium, LLC | 7 | $216 |
| Napo Pharmaceuticals Inc | 10 | $205 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $181 |
| Bausch Health US, LLC | 9 | $173 |
| Antares Pharma, Inc. | 7 | $152 |
| AstraZeneca | 8 | $139 |
| GSK | 6 | $122 |
| Alkermes, Inc. | 4 | $114 |
| Lilly USA, LLC | 4 | $96 |
| Verity Pharmaceuticals Inc. | 2 | $67 |
| Tolmar, Inc. | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Almatica Pharma LLC | 2 | $31 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Exact Sciences | 1 | $18 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,140 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 191 | $752,504 |
| SerostimSomatropin | 36 | $722,199 |
| TivicayDolutegravir Sodium | 73 | $209,843 |
| JulucaDolutegravir/Rilpivirine | 44 | $153,700 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $94,804 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $78,690 |
| PrezcobixDarunavir/Cobicistat | 20 | $63,446 |
| IsentressRaltegravir Potassium | 25 | $47,576 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $43,639 |
| PifeltroDoravirine | 22 | $38,073 |
| JardianceEmpagliflozin | 46 | $32,430 |
| TrulicityDulaglutide | 23 | $21,896 |
| OzempicSemaglutide | 20 | $18,763 |
| Repatha SureclickEvolocumab | 29 | $16,109 |
| BelsomraSuvorexant | 28 | $15,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,214 | $831,194228 claims |
| EMD Serono, Inc.Serostim | $553 | $722,19936 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Cabenuva, Dovato | $2,678 | $501,985145 claims |
| MerckIsentress, Pifeltro, Belsomra, Januvia | $389 | $109,34789 claims |
| Johnson & JohnsonPrezcobix | $242 | $63,44620 claims |
| Lilly USA, LLCTrulicity | $96 | $21,89623 claims |
| Novo NordiskOzempic | $16 | $18,76320 claims |
| Antares Pharma, Inc.Xyosted | $152 | $12,83222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.